Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP reduced its position in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 34.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 108,285 shares of the medical research company's stock after selling 57,166 shares during the quarter. Bridgewater Associates LP's holdings in Edwards Lifesciences were worth $8,016,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of EW. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences in the fourth quarter worth approximately $26,000. Millstone Evans Group LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Edwards Lifesciences in the fourth quarter valued at about $30,000. Roble Belko & Company Inc purchased a new position in Edwards Lifesciences in the fourth quarter worth about $46,000. Finally, Catalyst Capital Advisors LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $54,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Trading Down 3.8 %

Shares of EW stock traded down $2.71 on Monday, reaching $68.82. 1,936,671 shares of the company's stock were exchanged, compared to its average volume of 4,919,721. The company's fifty day simple moving average is $71.31 and its 200 day simple moving average is $70.92. The stock has a market capitalization of $40.46 billion, a PE ratio of 9.87, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Evercore ISI decreased their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and lifted their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research report on Wednesday, February 12th. Piper Sandler raised their price objective on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 12th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $78.55.

Insider Transactions at Edwards Lifesciences

In other news, Director Steven R. Loranger sold 5,739 shares of the firm's stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $76.42, for a total value of $438,574.38. Following the sale, the director now directly owns 60,372 shares in the company, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, April 14th. The stock was sold at an average price of $69.81, for a total transaction of $663,195.00. Following the completion of the transaction, the vice president now directly owns 47,206 shares in the company, valued at approximately $3,295,450.86. The trade was a 16.75 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.